What will be shared, what will be learned at IPCU 2018?

2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet as the year passed by, we were surprised to discover that many clinicians remained unaware of the data and its ability to deliver value across the care continuum especially when it comes to improving patient outcomes.

For example, did you know Cesium-131 brachytherapy leads to more rapid recovery of voiding function, with return to clinical baseline by 3 months and statistical baseline by 6 months post-treatment? Moreover, at a median last follow-up of 5.5 years post-treatment with Cs-131 prostate brachytherapy, there were no clinically significant changes in the EPIC or AUA scores from baseline.

Simply Put: Patients treated specifically with Cesium-131 seed implant (brachytherapy) return to their normal state of urinary voiding faster in the long run.

Read more about Dr. Ron Benoit’s findings from “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131” here.

At IPCU 2018, the Isoray team seeks to both share the data and also learn from urologists which are the critical channels through which they receive the latest science and industry development ‘news.’ To that end, we are working with the IPCU 2018 staff on convening a focus group designed to streamline the efficiency and increase the relevance of information we are with the urology community.

From a more clinical perspective, here are a few sessions from the program that really caught our attention:

  • Wednesday, January 24,  6:25 p.m. – 7:00 p.m. “LUGPA Economic Panel on Localized Treatments”
  • Thursday, January 25, 4:00 p.m. – 4:20 p.m. “Integrating Therapies Earlier: Therapeutic Layering”
  • Thursday, January 25, 5:20 p.m. – 5:40 p.m. “A Value-Based Healthcare Model and PCa”
  • Friday, January 26, 9:00 a.m. – 9:20 a.m. “Integrating the AUA Guidelines into Your Practice”
  • Friday, January 26, 3:50 p.m. – 4:10 p.m. “Future Options for Urology Practice Ownership”

If you are a urologist attending IPCU 2018 we want to meet with you to discuss the latest scientific data on prostate cancer treatment including brachytherapy: a modality that continues to decline in utility despite evidence that it generates superior outcomes with quality of life advantages for multiple prostate cancer indications.

Email Mike Krachon, mkrachon@isoray.com, to schedule a meeting onsite in Beaver Creek.

Bringing Compassion and Hope to Cancer Patients

Bringing Compassion and Hope to Cancer Patients

The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making a difference in the lives of patients diagnosed with different forms of cancer. Isoray Medical, Inc. [NYSE MKT:ISR] has...

read more